title: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
abstract: The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pts (32%), whereas 599 pts (58%) lacked such a donor, and information was not available in 107 pts. Compliance with allo-SCT was 82% (268 of 326). Cumulative incidences of relapse were, respectively, 32% versus 59% for pts with versus those without a donor (P < .001). Despite more treatment-related mortality (TRM) in the donor group (21% versus 4%, P < .001), disease-free survival (DFS) appeared significantly better in the donor group (48% +/- 3% versus 37% +/- 2% in the no-donor group, P < .001). Following risk-group analysis, DFS was significantly better for pts with a donor and an intermediate- (P = .01) or poor-risk profile (P = .003) and also better in pts younger than 40 years of age (P < .001). We evaluated our results and those of the previous MRC, BGMT, and EORTC studies in a meta-analysis, which revealed a significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile.
authors.affiliation: Department of Hematology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. j.cornelissen@erasmusmc.nl
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Cornelissen
authors.forename: Wim L J
authors.initials: WL
authors.lastname: van Putten
authors.forename: Leo F
authors.initials: LF
authors.lastname: Verdonck
authors.forename: Matthias
authors.initials: M
authors.lastname: Theobald
authors.forename: Emanuel
authors.initials: E
authors.lastname: Jacky
authors.forename: Simon M G
authors.initials: SM
authors.lastname: Daenen
authors.forename: Marinus
authors.initials: M
authors.lastname: van Marwijk Kooy
authors.forename: Pierre
authors.initials: P
authors.lastname: Wijermans
authors.forename: Harry
authors.initials: H
authors.lastname: Schouten
authors.forename: Peter C
authors.initials: PC
authors.lastname: Huijgens
authors.forename: Hans
authors.initials: H
authors.lastname: van der Lelie
authors.forename: Martin
authors.initials: M
authors.lastname: Fey
authors.forename: Augustin
authors.initials: A
authors.lastname: Ferrant
authors.forename: Johan
authors.initials: J
authors.lastname: Maertens
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
authors.forename: Bob
authors.initials: B
authors.lastname: Lowenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D019520:Living Donors; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000401:mortality; D014184:Transplantation, Homologous